Black patients with cutaneous lupus erythematosus (CLE) are more likely to have a family history of CLE and/or systemic lupus erythematosus (SLE) than those of other ethnicities, according to a recent study. The prevalence of CLE and/or SLE was 64% in Black patients compared with 45% in non-Black patients. “Providers…
A study in a mouse model of systemic lupus erythematosus (SLE) showed that treatment with methylprednisolone significantly improves survival rates in animals fed a regular diet — but not among those given a diet high in fats, which instead lessened the beneficial effects of the corticosteroid. In…
The Medical Research Foundation has awarded its sixth Emerging Leaders Prize to three lupus researchers in the U.K. The scientists received a total of £220,000 (around $269,000), funded by a gift in the will of Erina Herrick, a scientist with the disease who devoted her research to it.
Lupkynis (voclosporin) has been approved in Great Britain as a treatment for adults with active lupus nephritis by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA), Aurinia Pharmaceuticals, the therapy’s developer, announced. The MHRA’s approval came just a few months after the European Commission approved Lupkynis…
Women with systemic lupus erythematosus (SLE) whose disease went into remission right before becoming pregnant show better outcomes in the post-partum period, including a lower flare rate, according to a two-year follow up study. These findings highlight how “planned pregnancy counseling is fundamental when managing SLE patients,” the researchers wrote.
Belimumab continues to show a favorable risk-benefit profile in adults with systemic lupus erythematosus (SLE), according to safety data from six clinical trials. Researchers noted the findings “add to the evidence base supporting a positive benefit-risk profile of belimumab in the treatment of adult patients with SLE.” Data from…
The Lupus Foundation of America (LFA) has honored scientists Eric Morand and Joyce Chang for notable contributions to lupus research. Morand, PhD, of Monash University received the Evelyn V. Hess Award, and Chang, MD, of Boston Children’s Hospital and Harvard Medical School, was honored with the Mary Betty…
Reduced lymphatic drainage might explain why skin reactions to sunlight, or photosensitivity, may lead to systemic immune reactions and overall disease flareups in people with systemic lupus erythematosis (SLE), a study suggests. Data showed that the flow of the skin’s lymphatic fluid — which sends cells and molecular signals to…
The U.S. Food and Drug Administration (FDA) has agreed to allow Kyverna Therapeutics to begin clinical testing of KYV-101, the company’s investigational cell therapy for lupus nephritis, a form of lupus that causes kidney damage. Kyverna submitted a request, in the form of an investigational new drug…
Kira Pharmaceuticals will test KP-104, an investigational therapy for a blood-clotting disorder associated with systemic lupus erythematosus (SLE), using KORU Medical Systems’ easy-to-use subcutaneous (under-the-skin) Freedom System infusion device. “We selected KORU Medical based on their track record of helping patients receive high-value therapeutics subcutaneously in the…